LONDON BROKER RATINGS: Jefferies raises Hikma Pharmaceutical to 'buy'
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday: Read More
Price | 1,885.00p on 18-04-2025 | at 04:45:10
---|---|
Change | 0.00p 0% |
Buy | 1,887.00p |
Sell | 1,886.00p |
Buy / Sell HIK Shares |
Last Trade: | Buy 752.00 at 1,885.00p |
Day's Volume: | 0 |
Last Close: | 1,885.00p |
Open: | 0.00p |
ISIN: | GB00B0LCW083 |
Day's Range | 0.00p - 0.00p |
52wk Range: | 1,750.00p - 2,360.00p |
Market Capitalisation: | £4,155m |
VWAP: | 0.00p |
Shares in Issue: | 220m |
Hikma Pharmaceuticals (HIK) Latest Trades |
||||
Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
---|---|---|---|---|
Buy* | 752 | 1,885.00p | SI Trade |
16:35:16 - 17-Apr-25 |
Unknown* | 2,831 | 1,885.00p | OTC Trade |
16:35:16 - 17-Apr-25 |
Unknown* | 1,487 | 1,885.00p | OTC Trade |
16:35:16 - 17-Apr-25 |
Buy* | 136,359 | 1,885.00p | Suspected BUY Trade |
16:35:16 - 17-Apr-25 |
Buy* | 2 | 1,887.00p | Automatic Execution |
16:29:57 - 17-Apr-25 |
Buy* | 2 | 1,887.00p | Automatic Execution |
16:29:57 - 17-Apr-25 |
Sell* | 2 | 1,886.00p | Automatic Execution |
16:29:34 - 17-Apr-25 |
Buy* | 71 | 1,886.00p | Automatic Execution |
16:29:34 - 17-Apr-25 |
Buy* | 252 | 1,886.00p | Automatic Execution |
16:29:34 - 17-Apr-25 |
Buy* | 64 | 1,886.00p | Automatic Execution |
16:29:28 - 17-Apr-25 |
Hikma Pharmaceuticals (HIK) Regulatory News |
||
Date | Source | Headline |
---|---|---|
10th Apr 2025 2:36 pm | RNS | Director/PDMR Shareholding |
8th Apr 2025 1:47 pm | RNS | Director/PDMR Shareholding |
1st Apr 2025 9:30 am | RNS | Block listing Interim Review |
19th Mar 2025 10:10 am | RNS | Annual Financial Report and Notice of AGM |
4th Mar 2025 11:16 am | RNS | Director/PDMR Shareholding |
26th Feb 2025 7:00 am | RNS | Final Results |
10th Feb 2025 8:09 am | RNS | Notice of Results |
23rd Dec 2024 9:46 am | RNS | Director/PDMR Shareholding |
7th Nov 2024 3:30 pm | RNS | Outcome of Audit Tender Process |
7th Nov 2024 7:00 am | RNS | Trading Statement |